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Cognitive impairment has been documented in uremia
with partial improvement after dialysis. Nocturnal daily
hemodialysis (NHD) is a novel dialysis modality with multiple
benefits. Previous reports have shown marked improvements
in quality of life, cardiac function, resolution of peripheral
vascular disease, and reversal of central sleep apnea. We
hypothesized that patients maintained on NHD would
have better cognitive functioning than those receiving
conventional therapy. Using a longitudinal study design,
patients were tested at baseline and again after X6 months
NHD. At each of the two time points, a battery of 10
neuropsychological tests were used to evaluate three
domains of cognitive functioning – attention and working
memory skills, psychomotor efficiency and processing speed,
and learning efficiency. Clinical subjective symptoms for
cognitive functioning and depression were measured using
the Patients Assessment of Own Functioning inventory and
the Beck Depression Index. Twelve patients (six males, six
females) were recruited. Patients were aged 39.673.3 years
at the time of first testing. Thirty-three percent were diabetic,
with a mean Charlson comorbidity score of 3.572.0.
Depression (defined as 416 on the Beck Depression Index
score) was not seen in any patient. Over the 6-month period,
a 22% reduction in cognitive symptoms (P¼ 0.01), 7%
improvement in psychomotor efficiency and processing
speed (P¼ 0.02), and 32% improvement in attention and
working memory (P¼ 0.04) was seen. Learning efficiency
scores were unchanged. NHD may be associated with
improved general cognitive efficiency as measured by
psychomotor efficiency and attention and working memory.
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Increasingly, cognitive impairment is recognized in those
with renal disease.1–3 Brain function is an important
component of normal daily functioning. The ability to
understand, learn, and retain knowledge potentially impact
on many aspects of life, including work, recreation, and
societal role(s). In addition, brain function impacts on a
patient’s ability to adhere to complex medication and dietary
regimens, and their decision-making ability, for example,
dialysis modality selection.4 Significant decreases in cognitive
function have been reported in those with advanced renal
disease. Changes vary from subtle alterations in those with
mild, incidental, renal impairment to those who present in
extremis with delirium, coma, and convulsions requiring
immediate dialysis initiation. Impairment is, at least in part,
reversible with treatment. Earlier studies have reported
improved cognition with dialysis.5–8 Furthermore, there is
limited data suggesting further improvement after transplant-
ation from the National Cooperative Dialysis Study.9 These
data however, stem from the era when confounding owing to
the use of oral aluminum as a phosphate binder is common.
Subtle differences between hemodialysis (HD) and peritoneal
dialysis patients are reported, with those on peritoneal
dialysis having marginally better brain function.7,8 It remains
unclear if deterioration in mental function over time on
dialysis is present as the data did not correct for differences in
age, years of education, biochemical parameters, and
cerebrovascular risk.10
Characterization of brain function is complex, and best
summarized by considering different domains of functioning.
Although most domains will vary over time, each does so in
a characteristic pattern. One example is the speed at which
we process complex thoughts (psychomotor efficiency and
processing speed). This can vary over months to years with
most individuals showing a decline with age, and with ill
health (fluid domain). As illnesses resolve, fluid domains may
improve, and similarly as disease states worsen, deterioration
may be seen. Other fluid domains include the ability to pay
attention to a stimulus or to repeat a task (attention and
working memory), and the efficiency with which a person can
learn and retain information (learning efficiency). In contrast,
other domains remain relatively stable over time. These most
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often include language skills measured using vocabulary and
reading and general intellectual functioning (often termed
crystallized domains). As these skills peak in young adult-
hood and remain relatively stable over the adult lifetime, they
can be used to predict the optimal intellect of the
individual.11–13 To allow a comprehensive understanding of
brain function, multiple different measures must be included
in the neuropsychological test battery.
Nocturnal daily hemodialysis (NHD) is a novel dialysis
modality that, in observational studies, has been associated
with marked improvements in quality of life, cardiac
function, resolution of peripheral vascular disease, and
reversal of central sleep apnea.14 Unlike conventional HD
where treatment is given over an average of 4 h, three times a
week, patients treated with nocturnal HD are dialyzed for
anywhere between 6 and 10 h each night. Most chose to
perform dialysis 5–7 times a week. Whereas nocturnal dialysis
is rarely performed outside of the home setting, conventional
dialysis is commonly performed in hospital settings, private
clinic settings, and, although less commonly, at home. To
date no studies have looked at the effect on cognition of
conversion from standard thrice-weekly dialysis to nocturnal
HD. The objective of this pilot study was to quantify the
degree of improvement, if any, in three domains of cognitive
function (learning efficiency, attention and working memory,
and psychomotor efficiency and processing speed) when
patients were converted from standard thrice-weekly dialysis
to nocturnal HD. To minimize differences in baseline, general
intellectual functioning patients served as their own controls.
RESULTS
Patient demographics
A total of 14 patients agreed to participate. Two patients
underwent baseline tests only and are therefore not included
in the final results. Of these two, one patient withdrew
consent for testing after the 6-month period on NHD,
whereas the other decided not to proceed to home nocturnal
dialysis because of personal circumstances. These two
patients were similar in age, educational status, and baseline
scores to those who completed both tests. All patients were
significantly younger than the general population on dialysis
within our institution. Eleven of the 12 patients were
previously on home HD thrice weekly before conversion to
nocturnal HD. Four patients were diabetic. In addition, most
had significantly lower Charlson Comorbidity Index scores
than that seen in incident dialysis patients.15 No patients were
excluded on the basis of word-reading ability or depression.
Demographic details are shown in Table 1.
Baseline test results compared to healthy controls
Baseline Wide-Range Achievement Test-3 scores were
106.8713.7 with no individual falling below the reading
level associated with less than a Grade 6 education. Beck depre-
ssion scores were all within the normal range suggesting no
depression (mean value 9.174.0, range 2–15).16 Results were
compared with normal healthy controls using transformed
T scores, normalized for age, gender, and education status.
These data suggest that the patients accepted into the noctu-
rnal program have higher baseline cognitive function than
seen in the general population (Figure 1).
Change in medications, laboratory results, and individual
test scores
The second testing was carried out, on average, 8.3 months
after baseline testing, (range 6–13 months). On repeat testing
the Beck Depression Index scores suggested two patients were
clinically depressed (i.e. score X16). The median change in
Beck Depression Index scores was 4.0 (range –4 to þ 12) with
most scores improving only marginally. Comorbidity was
unchanged over time in all but one patient. This patient
developed severe depression requiring antidepressant medi-
cation and benzodiazepines during the 6-month period.
The number of medications fell on average by 2.25
medications (P¼ 0.01), with most reductions attributable to
better blood pressure control. A total of four patients were
started onto a benzodiazepine or other neuropsychological
drug during this time period, whereas two patients came off
sedative drugs. The dose of erythropoietin (or darbepoietin)
was not significantly different from baseline (Table 1).
Table 1 | Demographic details
Baseline
6 months
after NHD
Age in years (mean7s.d.) 39.673.3 —
Male/female ratio 1:1 —
Left handed (n) 2 —
Diabetes present (n) 4 —
CCI score (mean7s.d.) 3.572.0 3.572.0
# meds (mean7s.d.) 10.273.9 7.973.7
# taking meds causing
cognitive slowing
5 7
Epo (or equiv) dose/week
(mean7s.d.) (1000 IU)
44.2724.0 36.2729.6
Hgb (g/l) (mean7s.d.) 112715 122716
SCr (mmol/l) (mean7s.d.) 6607317 4017147
CCI, Charlson Comorbidity Index score; # meds, number of medications; Epo,
erythropoietin; Hgb, hemoglobin; NHD, nocturnal daily hemodialysis; SCr, serum
creatinine.
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Figure 1 | Baseline scores compared with healthy controls.
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Laboratory results were significantly different after 6
months on nocturnal dialysis. Serum creatinine levels
(Po0.01) fell while hemoglobin levels increased (not
statistically significant) (Table 1). Similarly, parathyroid
hormone levels fell from a mean (7s.d.) of 36.0726.7 to
19.7730.2 pmol/l (not statistically significant).
Baseline scores for each individual test performed are
shown in Table 2. Tests are grouped according to the domains
tested. The grooved pegboard scores in both dominant and
non-dominant hands were highly variable with multiple
patients showing large changes in performance, suggesting
both improvement and deterioration after conversion to
nocturnal dialysis (% change in score from baseline in
dominant hand – median¼ 0, range 45 to þ 30%; in non-
dominant hand – median¼1.8, range 62 to þ 26%).
Change in patient-perceived cognitive function
The mean Patients Assessment of Own Functioning score
fell from 36.9718.7 to 26.7714.4, reflecting significant
improvement in perceived cognition (P¼ 0.01) (Figure 2).
Change in three primary domains of cognition
Improvement was seen in all three domains of function.
Psychomotor efficiency and processing speed improved by an
average of 7% (P¼ 0.02) and learning efficiency by an
average of 4.9% (NS). The largest mean improvement was
seen on attention and working memory (32% improvement,
P¼ 0.04) (Figure 3). The results for individual tests are
shown in Table 2.
DISCUSSION
These data support our initial hypothesis that cognitive
function would improve when patients were converted to
nocturnal dialysis. Baseline scores suggest that the nocturnal
patient population is a selected group who cognitively
perform well, despite uremia. Most patients performed
within the high average range on tasks, which measure
attention and working memory as well as those involving
psychomotor efficiency and processing speed. Surprisingly, a
large proportion of patients performed below average on the
Grooved Peg Test despite good performance on other tests
suggesting disproportionate neuropathic or neuromuscular
involvement. This may have implications for a patients ability
to perform certain fine motor tasks with the hand, for
example, setting up the machine, although because of the
high degree of variability we believe subsequent studies are
needed to confirm this observation.
Table 2 | Baseline and follow-up scores on neuropsychometric testing
Test
Mean score at
baseline (7s.d.)
Mean score at
second testing (7s.d.)
Mean % change
from baseline
Boston naming test 54.674.1 56.272.7 3.1
COWA 38.9715.6 45.677.4 17.1
Category fluency 51.177.5 50.878.2 0.5
Digit span (scaled score) 10.372.9 11.273.2 8.1
Letter num (raw score) 11.172.3 11.972.2 7.5
Spatial span (scaled score) 10.572.2 10.872.8 3.2
Trails A time (s) 21.377.2 20.873.8 2.7a
Trails B time (s) 57.7717.0 49.3710.7 14.6a
Digit symbol (scaled score) 9.872.8 10.373.0 4.2
Pegs, dominant hand (T-score) 40.2715.4 37.1710.0 0.1a,b
Pegs, non-dominant hand (T-score) 39.8712.9 42.3713.6 10.0a,b
CVLT total words 58.278.4 62.679.5 4.9
COWA, Controlled Oral Word Association Test; CVLT, California Verbal Learning Test.
aScoring based upon times, that is, lower scores are associated with improvement.
b% change in pegs score varied widely (see text for details).
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Figure 2 | Change in Patients Assessment of Own Functioning
scores.
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Figure 3 | Change in psychomotor efficiency and speed (top) and
attention and working memory scores (bottom) for individual
patients. Each line represents one patient.
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The data presented show significant improvement in the
patients own perception of their function, in their psycho-
motor efficiency and processing speed, and in attention and
working memory. Furthermore a trend to improvement is
seen across the individual tests used, in addition to all three
domains examined. (This pilot study was not designed to
have sufficient power to show statistical significance with
individual tests.) The magnitude of change in the patients’
own assessment of cognitive function was large relative to
that measured on the objective psychometric measures.
Whereas some of the subjective changes may be attributed
to improved mood, or to the sense of independence and
achievement associated with mastering and performing
nocturnal dialysis at home, we believe a significant
component is actually related to the modality change itself.
In our population, 11 of the 12 individuals had previously
been on home dialysis and therefore one assumes had a high
self-esteem. Furthermore, Beck depression scores revealed an
increased prevalence of depression at the time of the second
testing.
Up to 40% of variability in brain function can be
explained by demographic variables, including age, gender,
and race.17 By using a longitudinal study design, with
patients acting as their own controls, we were able to decrease
measurement noise associated with demographic differences.
We therefore believe the changes seen in cognition between
the two sittings are more likely to be attributable to nocturnal
dialysis.
Bias arising from repeated testing (training effect or
test–retest bias) has been widely studied in the psychometric
literature.18,19 In many cases, repeating a test frequently will
lead to learned behavior and improved scores, whereas in
mild or subclinical cases cognitive deficits can be uncovered
by multiple assessments carried out in 1 day.20 Most of the
literature reports practice effects in tests repeated within a
relatively short time frame (days to weeks) with smaller
practice effects being seen after 16 weeks. Studies in both
healthy volunteer populations and those with cognitive
impairment suggest that practice effects are maximal between
the first and second administration of the test, and that
between the third and fourth administration patients show
smaller or no practice effects. We used three strategies to limit
practice effects: (i) patients were tested at least 26 weeks after
the baseline testing (ii) in each of the two settings, patients
underwent a practice session as part of the administered tests.
This consisted of a training set of tests, followed shortly
thereafter by the tests themselves; and (iii) alternate forms
(i.e. different versions of the same test) were used. Alternate
forms have been shown to lessen practice effects.21–24 Despite
these measures, it is possible that some of the differences seen
may have been in part related to practice effects.
Although our study is not designed to identify why
cognition may improve with NHD, there are many
hypothetical reasons. One striking difference between con-
ventional and nocturnal HD is the vastly improved toxin
clearance seen with nocturnal dialysis. Previous studies
looking at cognition in renal patients were unable to show
a relationship between dialysis dose and cognitive impair-
ment, however, in comparison to the difference in dialysis
clearances on conventional dialysis and nocturnal dialysis,
the dose variations were small.25 It remains tempting to
speculate that changes are purely on the basis of improved
toxin clearances. Improved cognition, as a consequence of
neuroprotection, has been seen with the use of erythropoietin
in both dialysis patients,26,27 and in other patient groups. In
this study, as in previous work by our group,28 the
hemoglobin showed a trend toward higher levels despite an
decrease in total dose of erythropoietin administered. The
change in cognition is therefore unlikely to be related directly
to the administration of erythropoietin. Improvements in
cognition may be in part explained by improved parathyroid
hormone control.29–31 Mean parathyroid hormone levels
trended down over the 6-month period, although statistical
significance was not seen in this study (previous work has
already demonstrated significant improvements over
time32–34). The mechanism by which parathyroid hormone
control can improve cognitive function remains unknown.
Changes in blood pressure or in blood pressure medications
may also impact on cognitive function. Rigorous blood
pressure monitoring was not a component of this study,
although previous authors have reported improved blood
pressure control with NHD. Concomitantly, we did see a
reduction in the medication burden in this cohort.
Subsequent detailed studies using parallel group studies with
psychometric studies, positron emission tests, or functional
magnetic resonance imaging may elucidate this further.25
We chose to use psychometric methods to evaluate
cognition in our study in preference to functional magnetic
resonance imaging, positron emission test, or visual-evoked
potentials, as we felt there was a good correlation between
improved results on psychometric measures and employment
ability, functional capacity, and quality of life. By doing so,
we may have missed smaller, subtle improvements in brain
function. We recognize that our study was underpowered to
show statistical significance in individual tests, but believe
that the pre hoc specified domains of functioning add to the
clinical significance of our findings. The patients enrolled
were mostly young persons with minimal cognitive impair-
ment at baseline, making it less likely that we would see large
improvements in brain function. The observed improvement
in symptoms is encouraging and suggests that further
changes in brain plasticity may be seen over time, particularly
in a more vulnerable population. Subsequent work to
characterize the nature of the improved cognition is certainly
needed. However, based upon the results shown here, we
believe that nocturnal dialysis offers a better functional life
for our patients.
MATERIALS AND METHODS
Study population
In 2003, the NHD program at the University Health Network
underwent expansion, with a number of patients suitable for and
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interested in home dialysis being identified within a short time
frame. These patients were placed on a waiting list to be
scheduled to undergo intensive training in how to perform
nocturnal dialysis in the home setting. Although not a requirement
for study participation, many initially listed for home training
were previously on home dialysis. All patients placed on the
waiting list for training for NHD between April 2003 and December
2003 were identified and approached to participate in the study.
Patients were included if they were stable on thrice-weekly HD at
baseline, were scheduled for training for NHD, spoke English
fluently, and had a minimum educational of Grade 6 or higher.
Patients with a previous history of head injury requiring overnight
hospitalization, known learning disabilities, a documented past
history of stroke or transient ischemic attacks, or depression were
excluded.
On NHD, dialysis sessions are tailored to individual needs. Most
patients undergo dialysis for a period of 6–8 h, 5–7 times a week.
Gambro Integra dialysis machines are pre-programmed to allow
dialysate flow speeds of 300 ml/min, with average blood pump
speeds of 300 ml/min. Single pool Kt/V values are higher than with
conventional dialysis, reaching on average more than 5.0, with
disproportionate increases in middle molecule clearance. Commer-
cially available dialysate solutions are used, although, in all cases,
prescriptions are tailored to the individual.
Study design
Using a prospective longitudinal design, patients underwent a
battery of psychometric studies at baseline and again when
established on NHD. Baseline testing was that carried out before
training when the patients were established on standard three times
weekly HD therapy. Testing was repeated when the patient had
been on NHD for at least 6 months. All psychometric tests were
administered between 1 and 8 h after dialysis to limit variability
across the intradialytic cycle.35,36 Clinical and medication details
were abstracted from the clinical chart. Blood testing was carried
out, when possible, on the day of testing or within a 2-week
time period.
Tests administered
The Beck depression score was administered at baseline to all patients
to screen for morbid depression.37 By protocol, testing was delayed
until after depression had been adequately treated. Patients with
untreated or non-resolving depression at baseline were excluded. In
addition the Wide-Range Achievement Test-3 Reading Test was
performed at baseline. This test provides a measure of word-reading
ability and was used to screen for English reading ability. By
protocol patients were excluded on the basis of a reading score at
Grade 5 level or less.
The clinical impact of cognitive impairment on life and activities
of daily living was measured using the Patient Assessment of Own
Functioning score.38 This score correlates inversely with quality of
life and functionality and is a good marker of the patients own
cognitive well being.39
A battery of 10 psychometric tests was used. Alternate forms
were used at the initial and follow-up visits.
California Verbal Learning Test-II. The California Verbal
Learning Test-II provides measures of verbal learning, immediate
and delayed recall, and recognition memory. It requires the
examiner to read a 16-word list and ask the subject to recall as
many words as possible.40
Digit Span. This test measures auditory focused attention and
working memory.41 Subjects are read a series of numbers that they
are asked to repeat back. The number length is gradually increased
to a max of seven digits. Recent normative data are available on 2450
people from age 16 to 89 for Digit Span.41
Letter–number sequencing. This is a test of auditory working
memory.42 The examiner reads a series of numbers and letters. The
subjects task is to say the numbers in numerical order, followed by
the letters in alphabetical order.
Spatial Span. Subjects are shown a board with nine identical
blocks. The examiner taps the blocks in a variable sequence, and asks
the subject to copy them using the same sequence both forwards and
backwards. The test provides a measure of working memory for
visual–spatial information.41
Digit Symbol. Subjects are shown 10 symbols each with a
corresponding letter or number. Subjects are then asked to
‘translate’ a document with these codes as quickly and accurately
as possible. Digit Symbol measures psychomotor speed.43
Grooved Pegboard test. Subjects are asked to place asymme-
trical metal pins into a grooved pegboard while being timed. The
test is repeated with both the dominant and non-dominant hands.
Results correlate with manual dexterity and psychomotor efficiency
and processing speed.44
Trail Making Test – Forms A and B. Patients are asked to trace
a line between sequential letters (Trails A) or alternating letters and
numbers (Trails B) drawn on a sheet of paper. This test measures
psychomotor speed, visual scanning and alternating attention (form
B).43 The time taken correlates inversely with psychomotor speed.
Category Fluency. This test is a measure of verbal and
language fluency. Subjects are asked to name as many animals,
fruits, and vegetables in a fixed time period.
Boston Naming Test. This is a 60-item naming test with a high
test–retest reliability score. Line diagrams are shown to subjects who
are asked to name the items. Higher scores indicate good verbal
fluency and allow discrimination between Alzheimer’s disease, other
dementing illnesses and normal subjects
The Controlled Oral Word Association Test. The controlled
oral word association test also examines language fluency, in
particular phonetic association. Subjects are asked to name as many
words beginning with a certain letter within a fixed time period. F,
A, and S are the most commonly used letters.44
Clinical variables
Demographic data collected included the age of the individual,
gender, and years in formal education. Clinical data included the
cause of renal disease, the presence of diabetes, hypertension, and
other comorbid illnesses. Comorbidity was reported using the
Charlson Comorbidity Index.45 Medications being used at both
visits were recorded. Benzodiazepines, opiates, sedatives, anti-
depressants, antiepileptic, and anti-Parkinsonian drugs were con-
sidered as medications causing cognitive slowing. The use of
erythropoietin, including the mean weekly dose, was recorded at
both visits. Biochemical data collected will include hemoglobin,
serum creatinine, serum calcium, serum phosphate, serum albumin,
and intact parathormone levels.
Statistical analysis
Scores were reported both as raw scores and as normalized scores. In
normalized scores, data are fit to a normalized scale allowing direct
comparisons across scores. Composite scores were calculated using
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definitions that had been specified before the study was commenced.
Three main domains – learning efficiency, attention and working
memory, and psychomotor efficiency and processing speed were
calculated. Attention and working memory scores were calculated
from the mean standardized scores for Digit Span and Spatial Span.
Psychomotor efficiency and processing speed was defined as the
mean of the standardized score for Digit Symbol and Trails B test.
Learning efficiency was defined as the total words score from the
California Verbal Learning test.
Demographic data were reported using means7s.d. or med-
ian7quartiles where appropriate. Comparisons between baseline
and NHD demographic data were made using the paired non-
parametric tests (Wilcoxon’s signed rank) using an alpha level of
0.05. Individual cognitive test scores are reported as mean7s.d.
This study was in compliance with the local research ethics
board, and the Tri-council policy statement, ICH/GHP Guidelines,
and Part C, Division 5 of the Food and drug regulations of Health
Canada.
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